Clarivate

MARCH 14, 2024

Nitrosamines have garnered significant attention from the pharmaceutical industry due to their detection in commonly prescribed medications for conditions like type 2 diabetes, high blood pressure, and heartburn. [1] Manufacturers, healthcare providers, and consumers alike face the need to quickly adapt.

Pharmaceutical 52

Pharmaceutical Manufacturing Food Healthcare Provider 52

European Pharmaceutical Review

NOVEMBER 8, 2022

Pharmaceutical manufacturers have submitted Citizen Petitions raising safety or efficacy concerns about proposed competing generic and biosimilar products, and such submissions often delay FDA approval of the proposed products while the FDA resolves the pending petitions.

Food and Drug Administration 52

Food and Drug Administration Pharma Prescription Manufacturing 52

Clarify Health

OCTOBER 26, 2021

The American Medical Association’s 2021-2023 Organizational Strategic Plan to Embed Racial Justice and Advance Health Equity In February 2021, the American Society of Clinical Oncology (ASCO) and Friends of Cancer Research issued new recommendations in five specific areas to broaden oncology trial eligibility criteria to include minorities.

Food and Drug Administration 52

Food and Drug Administration Recruitment Pharmaceutical manufacturing Medical 52

Impetus Digital

NOVEMBER 23, 2023

With the end of the year quickly approaching, you will likely see multiple articles on the key trends of 2023 and predictions for 2024 start popping up. A version of this article was previously published in the Journal of mHealth. Many of these will discuss the expanding role and capabilities of AI and machine learning in the Pharma space.

Education 52

Education Healthcare Provider Physicians Pharma 52